Specifically, the tumor initiation ability of SCC CSCs measured by serial limit-dilution transplantation assays seems to be governed by α6β1 but not CD34, as only α6hiβ1hi populations, regardless of CD34 expression level, can initiate secondary tumors. This evidence concerns the gene CD34 and neoplasm.